Kiniksa Pharmaceuticals (KNSA) Stock Statistics & Valuation Metrics

Kiniksa Pharmaceuticals has a market cap or net worth of $2.24B. The enterprise value is $2.01B.

Kiniksa Pharmaceuticals has 43,472,927 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kiniksa Pharmaceuticals’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -11.31%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Kiniksa Pharmaceuticals had revenue of 423.24M and earned -43.19M in profits. Earnings per share was -0.60.

In the last 12 months, operating cash flow was 66.95M and capital expenditures -457.00K, giving a free cash flow of 66.49M billion.

Kiniksa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Kiniksa Pharmaceuticals upcoming earnings date is Nov 4, 2025, Before Open (Confirmed).

Kiniksa Pharmaceuticals as a current ratio of 3.30, with Debt / Equity ratio of 1.97%

In the past 12 months, Kiniksa Pharmaceuticals has paid 7.04M in taxes.

Kiniksa Pharmaceuticals EV to EBITDA ratio is -27.16, with an EV/FCF ratio of 48.76.

Kiniksa Pharmaceuticals has $307.78M in cash and marketable securities with $9.77M in debt, giving a net cash position of -$298.02M billion.

Gross margin is 77.35%, with operating margin of -10.78%, and net profit margin of -10.21%.

The average price target for Kiniksa Pharmaceuticals is $43.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy